Skip to main content

December 2022, Vol 12, No 12

Self-insured employers, perhaps even yours, are being presented with programs called “specialty carve-outs” as an opportunity for saving significant money on the drug portion of their employee benefits. Read More ›

The treatment of acute myeloid leukemia (AML) has entered a new era, with the use of more potent therapies, such as targeted agents and venetoclax (Venclexta). Read More ›

Results from a new study revealed that radiation oncologists tend to discuss sexual side effects in women undergoing treatment for cervical cancer far less frequently than they discuss sexual side effects in men undergoing treatment for prostate cancer. Read More ›

A shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer, according to the results of the phase 3 Prostate Cancer Study 5 (PCS5) trial. Read More ›

According to findings from a phase 3 trial presented at ASTRO 2022, the addition of stereotactic body radiation therapy (SBRT) to sorafenib (Nexavar) can lengthen overall survival (OS) and delay tumor progression in patients with unresectable advanced hepatocellular cancer (HCC) without compromising quality of life. Read More ›

Updated results from the ECHELON-1 clinical trial showed that the combination of brentuximab vedotin (Adcetris; BV) plus doxorubicin, vinblastine, and dacarbazine (AVD) as first-line therapy improves overall survival (OS) in patients with stage III-IV classical Hodgkin lymphoma compared with standard therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Read More ›

At the AVBCC 12th Annual Summit in 2022, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. Read More ›

According to published results from a phase 3, prospective, multicenter, randomized clinical trial, the addition of the CD-30–targeted antibody–drug conjugate brentuximab vedotin (Adcetris) to standard chemotherapy can reduce the risk for relapse in this population of patients while providing a better tolerability profile. Read More ›

Standardizing biosimilar adoption in oncology through the electronic health record can improve biosimilar utilization and reduce health system costs. Read More ›

Care management services are designed to engage patients as active partners in their healthcare so they can effectively manage their complex medical conditions. Read More ›

Page 1 of 2